ライフサイエンスコーパス: TSP-1

1 TSP-1 also inhibited VASP phosphorylation stimulated by

2 TSP-1 and the CD36 binding peptide induced phosphorylati

3 TSP-1 binds to matrix components, proteases, cytokines,

4 TSP-1 blockade also prevents the PH in a second model, c

5 TSP-1 converts latent transforming growth factor-beta1 (

6 TSP-1 deficiency resulted in significantly reduced TGF-b

7 TSP-1 disruption abrogated age-associated capillary rare

8 TSP-1 disruption did not affect inflammatory gene expres

9 TSP-1 disruption did not significantly affect weight gai

10 TSP-1 expression was induced in endothelial cells (ECs)

11 TSP-1 functioned in a positive feedback loop to stabiliz

12 TSP-1 has been shown to reduce von Willebrand factor (VW

13 TSP-1 induced in ECs by reactive oxygen species (ROS) mo

14 TSP-1 is a potent antiangiogenic and proatherogenic prot

15 TSP-1 is reported to be a p53-target gene and p53 is a k

16 TSP-1 plays no direct role in the regulation of its own

17 TSP-1 prevented PGE-stimulated cAMP accrual and phosphor

18 TSP-1 supports an anti-inflammatory phenotype of microgl

19 TSP-1 tethering of ERK in the cytoplasm promoted a level

20 TSP-1 upregulation in the diabetic heart prevents chambe

21 TSP-1-/- animals had more extensive postinfarction remod

22 TSP-1/CD36 interactions were shown to regulate angiogene

23 matrix protein (COMP) and thrombospondin 1 (TSP-1) correlated moderately well with the MRSS, but the

24 + transients, synaptogenic thrombospondin 1 (TSP-1) release, and synapse formation.

25 Basal muscle expression of thrombospondin 1 (TSP-1) was approximately 900% greater in 14d- and 28d-tr

26 (VEGF), but high levels of thrombospondin 1 (TSP-1), predicted liver dysfunction after resection.

27 in, and its natural ligand thrombospondin 1 (TSP-1).

28 ted kinase II (ROCKII) and thrombospondin 1 (TSP-1).

29 he anti-angiogenic protein thrombospondin-1 (TSP-1 PM).

30 g to the type 1 repeats of thrombospondin-1 (TSP-1) and activating Fyn tyrosine kinase and MAPK pathw

31 cellular components [i.e., thrombospondin-1 (TSP-1) and fibronectin (FN)] seem to trigger different p

32 and elevated expression of thrombospondin-1 (TSP-1) and its receptor CD36, anti-angiogenic factors.

33 d the CD47-binding partner thrombospondin-1 (TSP-1) and that treatment of aged erythrocytes with a TS

34 p53 led to a deficiency in thrombospondin-1 (TSP-1) expression, a potent antiangiogenic protein, and

35 roteins and proteoglycans, thrombospondin-1 (TSP-1) functions at the interface of the cell membrane a

36 The N700S polymorphism of thrombospondin-1 (TSP-1) has been identified as a potential genetic risk f

37 eading to up-regulation of thrombospondin-1 (TSP-1) in DCs.

38 Thrombospondin-1 (TSP-1) inhibits growth factor signaling at the receptor

39 Thrombospondin-1 (TSP-1) is a glycoprotein considered as a key actor withi

40 Thrombospondin-1 (TSP-1) is a large extracellular matrix protein secreted

41 Thrombospondin-1 (TSP-1) is a major activator of latent transforming growt

42 Thrombospondin-1 (TSP-1) is a multifunctional protein which is secreted in

43 Thrombospondin-1 (TSP-1) is a multimodular glycoprotein with three EGF-lik

44 and angiogenesis, whereas thrombospondin-1 (TSP-1) is a potent angiogenic inhibitor.

45 Thrombospondin-1 (TSP-1) is an endogenous inhibitor of angiogenesis encode

46 Thrombospondin-1 (TSP-1) is an endogenous inhibitor of angiogenesis whose

47 how TGF-beta activation by thrombospondin-1 (TSP-1) is both required and sufficient for the developme

48 n anti-angiogenic protein, thrombospondin-1 (TSP-1) is down-regulated in the prostate and liver of U1

49 Thrombospondin-1 (TSP-1) is one of the anti-angiogenic factors whose synth

50 Here we show that thrombospondin-1 (TSP-1) prevents cAMP/protein kinase A (PKA) signaling th

51 Thrombospondin-1 (TSP-1), a potent antiangiogenic and proatherogenic prote

52 creasing evidence suggests thrombospondin-1 (TSP-1), a potent proatherogenic matricellular protein, a

53 ors, including endostatin, thrombospondin-1 (TSP-1), and pigment epithelium-derived factor (PEDF), as

54 f a synaptogenic molecule, thrombospondin-1 (TSP-1), apart from supporting neuronal integrity.

55 and in vivo validations on thrombospondin-1 (TSP-1), because it has been previously shown to be impor

56 he second type-1 repeat of thrombospondin-1 (TSP-1), is known to possess antiangiogenic activity.

57 The matricellular protein, thrombospondin-1 (TSP-1), is prominently expressed during tissue repair.

58 tumstatin, endostatin, or thrombospondin-1 (TSP-1), to address the role that these endogenous angiog

59 gulating the production of thrombospondin-1 (TSP-1)--known earlier for both its anti-angiogenic and p

60 F-beta-activating protease thrombospondin-1 (TSP-1).

61 e anti-angiogenic molecule thrombospondin-1 (TSP-1).

62 e type-1 repeats (3TSR) of thrombospondin-1 (TSP-1).

63 an antiangiogenic factor, thrombospondin-1 (TSP-1).

64 mediates up-regulation of thrombospondin-1 (TSP-1).

65 ed pinpoint this factor as thrombospondin-1 (TSP-1).

66 the angiogenesis inhibitor thrombospondin-1 (TSP-1).

67 retinal space mediated by thrombospsondin-1 (TSP-1) activation of CD47.

68 anti-angiogenic peptides (thrombospondin-1, TSP-1; and endostatin) as well as pro-angiogenic factors

69 We generated a TSP-1-deficient mouse model of a partial hepatectomy (PH

70 In a TSP-1 promoter-driven luciferase reporter assay, p53 tra

71 ed TSP-1 transcription and the activity of a TSP-1 promoter-reporter construct stimulated by high glu

72 d that treatment of aged erythrocytes with a TSP-1-derived peptide enabled their phagocytosis by huma

73 We examined thrombospondin-1 (THBS1, alias TSP-1) expression in human synovial tissue (ST) during t

74 ly 50% of rejected WT allografts, nearly all TSP-1 null allografts succumbed to rejection.

75 a demonstrate that NOL7 significantly alters TSP-1 expression and may be a master regulator that coor

76 a demonstrate that NOL7 significantly alters TSP-1 expression and may be a master regulator that coor

77 ngle amino acid changes in TSP-4 (A387P) and TSP-1 (N700S).

78 Stroke increases CD36 and TSP-1/2 mRNA levels in the ipsilateral hemisphere at acu

79 I44) and sialoadhesin (Siglec-1) to COMP and TSP-1 in multiple regression analyses significantly impr

80 r the aberrant angiogenesis in diabetics and TSP-1 involvement in development of various vascular dia

81 educed circulating antigen levels of HNE and TSP-1.

82 Purified HC.HA did not contain PEDF and TSP-1 but did contain IGFBP-1 and platelet factor 4 whil

83 Cyclin D1 repressed ROCKII and TSP-1 expression, and the migratory defect of cyclin D1(

84 Cellular abundance of Txr1 and TSP-1 varied inversely, and alteration of the level of b

85 r to control levels, but both basal VEGF and TSP-1 were elevated (P < 0.05).

86 e in pro-angiogenic BDNF and anti-angiogenic TSP-1/CD36.

87 The epitope for C6.7 anti-TSP-1 was localized to Glu-609 in the EGF2 module.

88 l basis for the physical interaction between TSP-1 and BMP-4.

89 r therapy, a reciprocal relationship between TSP-1 and NR4A2 expression levels was measured in patien

90 to undergo a conformational change and bind TSP-1.

91 kinase inhibitor, SB203580, instead blocked TSP-1 expression and a p38 activator, MKK6, increased TS

92 Moreover, inhibition of Src kinases blocked TSP-1-mediated regulation of cAMP concentrations and the

93 inhibited angiogenesis and blockade of both TSP-1 and CD36 accelerated angiogenesis.

94 dicated that P2Y(4) receptors stimulate both TSP-1 expression and release.

95 Disruption of CD47-TSP-1 interaction by TSP-1-blocking antibodies or down-regulation of CD47 on

96 ositive T cells resulted from stimulation by TSP-1 null APCs relative to WT ones.

97 identified three potential biomarkers CD163, TSP-1 and IL-1RII whose response to steroids was signifi

98 iated antiangiogenic pathway induced by CD36-TSP-1 interaction that inhibits VEGFR2 signaling and the

99 We hypothesized that CD36-TSP-1 interaction recruits Src homology 2 domain-contain

100 These data point to a role for CD47-TSP-1 interactions in regulating cell-fusion events invo

101 Disruption of CD47-TSP-1 interaction by TSP-1-blocking antibodies or down-r

102 Blockade of CD47-TSP-1 interactions also inhibits receptor activator for

103 Disruption of CD47-TSP-1 interactions or preventing the recruitment of DCs

104 Unlike in macrovascular cells, TSP-1 protein levels are dramatically decreased in respo

105 n would enable glycosaminoglycans to cluster TSP-1.

106 In the developing CNS, TSP-1 is involved in neuronal migration and adhesion, ne

107 At D14 and D28, TSP-1 protein was not different compared to baseline lev

108 heart, we generated and characterized db/db TSP-1(-/-) (dbTSP) mice.

109 ransduced HCT116 cells, leading to decreased TSP-1 levels.

110 Our work defines TSP-1 as a novel immediate early gene that could be a po

111 We therefore conclude that APC-derived TSP-1 suppresses their capacity to allosensitize T cells

112 ombinant N700S fragments or platelet-derived TSP-1.

113 role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis.

114 NOL7 also increases endogenous TSP-1 mRNA half-life.

115 riptional networks, suggesting that enhanced TSP-1 expression may help restore tissue homeostasis dur

116 53 expression in these tumors re-established TSP-1 expression.

117 In this study, the authors examined TSP-1 as a potential regulator of these phenotype of mic

118 Exogenous TSP-1 reduced significantly PGE-mediated inhibition of b

119 l of a partial hepatectomy (PH) and explored TSP-1 induction, progression of liver regeneration, and

120 Following Schistosoma exposure, TSP-1 levels in the lung increase, via recruitment of ci

121 Future strategies targeting APCs for TSP-1 upregulation may thus be effective in promoting al

122 rating liver were the responsible factor for TSP-1 induction.

123 tudies introduce a new signaling pathway for TSP-1, CD36, and Syk, and address the role of these prot

124 We also define a new role for TSP-1 and CD36 in the activation of the VEGFR-2 signalin

125 These data reveal a new role for TSP-1 in promoting platelet aggregation through modulati

126 These results document a role for TSP-1 in regulating CTGF gene and protein expression in

127 Antigen-presenting cells, derived from TSP-1 null, but not from wild-type mice, activate T cell

128 Further, TSP-1 blockade attenuates hypercalcemia induced by parat

129 Like many angiogenesis-related genes, TSP-1 expression is tightly controlled by various mechan

130 perative alpha-granule release profile (high TSP-1/low VEGF) showed substantially worse postoperative

131 ecipitation confirmed that recombinant human TSP-1 can bind BMP-2 and -4 and antagonize their effects

132 1 in diabetic atherosclerosis, hyperglycemic TSP-1(-/-)/ApoE(-/-) double knockout mice were compared

133 We have identified TSP-1 as an inhibitory element in regulating liver regen

134 Our data identify TSP-1 as a p53 target that contributes to maintaining Ra

135 Here we identify TSP-1 as the molecule with the highest induction level a

136 ability in response to VEGF are decreased in TSP-1-null mice and isolated endothelial cells.

137 Mice deficient in TSP-1, despite appearing normal at birth, develop a chro

138 such as TNF-alpha and iNOS is detectable in TSP-1 null retina compared with WT controls.

139 hanced migration of microglia is detected in TSP-1 null retina, and these microglia express markers a

140 c kidney injury was demonstrated directly in TSP-1 null mice, which showed significant protection aga

141 rgic signaling may be an important factor in TSP-1-mediated cell-matrix and cell-cell interactions su

142 with extracellular ATP caused an increase in TSP-1 expression in a time- and concentration-dependent

143 oadenosine, caused a significant increase in TSP-1 expression.

144 Knockdown of B-Raf(V600E) resulted in TSP-1 down-regulation and a reduction of adhesion and mi

145 ated region, and its elimination resulted in TSP-1 reactivation, impaired angiogenesis in Matrigel pl

146 for P2 receptor/protein kinase signaling in TSP-1 expression induced by trauma.

147 the production of BrM components, including TSP-1, PEDF, and tropoelastin in vitro and increased the

148 GF and IL-8 expression, but did not increase TSP-1 expression.

149 ased VEGF and IL-8 expression, but increased TSP-1 expression in BT474 breast cancer cells that expre

150 on of recombinant GFAT resulted in increased TSP-1 levels.

151 ression and a p38 activator, MKK6, increased TSP-1 expression.

152 proliferation and VEGF production, increased TSP-1 and endostatin, and inhibited corneal neovasculari

153 ied with inhibition of hyperglycemia-induced TSP-1 expression and reduced protein O-glycosylation fol

154 We found that oncogenic Kras-induced TSP-1 upregulation in a p53-dependent manner.

155 inases or Akt inhibited ATP- and UTP-induced TSP-1 expression.

156 Infarcted TSP-1-/- mice exhibited sustained upregulation of the ch

157 protein glycosylation efficiently inhibited TSP-1 transcription and the activity of a TSP-1 promoter

158 mRNA, expression of angiogenesis inhibitors TSP-1 and thrombospondin-2 (TSP-2).

159 g-standing cardiovascular benefits, inhibits TSP-1 expression in glucose-stimulated human aortic smoo

160 Interestingly, TSP-1 counteracted the increased neuronal excitability a

161 monoclonal antibodies to human TSP-2 and its TSP-1 homolog have given insights into the structure of

162 nes raise this threshold which leads to less TSP-1 production, while signals that promote the generat

163 n uveitis, in the presence of TLR-4 ligands, TSP-1 is initially produced by recruited macrophages but

164 cytometry analysis revealed that, in males, TSP-1 knockout reduced macrophage infiltration and phago

165 t-like synoviocytes (FLSs) expressed minimal TSP-1 mRNA levels with high transcript levels of NR4A2,

166 therapeutic strategies designed to modulate TSP-1 synthesis in conditions that simulate tumor and pe

167 Moreover, TSP-1 inhibited the action of serum BMPs.

168 betic db/db mice exhibited marked myocardial TSP-1 upregulation in the interstitial and perivascular

169 how that in cultured rat spinal cord neurons TSP-1 decreased neuronal excitability by reducing the ac

170 s of heparin further enhances the ability of TSP-1 to participate in high affinity binding to glycosa

171 In the absence of TSP-1, microglia in uninjured retina express major histo

172 glucose, we demonstrated that activation of TSP-1 transcription is mediated by the hexosamine pathwa

173 whether the altered VWF-reducing activity of TSP-1 underlies the observed prothrombotic phenotype.

174 angiogenesis in this model as application of TSP-1 inhibited angiogenesis and blockade of both TSP-1

175 -1 in IR injury and showed colocalization of TSP-1 with activated caspase-3.

176 Lastly, the plasma concentration of TSP-1 is significantly increased in subjects with sclero

177 The contribution of TSP-1 upregulation to the modulation of tumorigenesis in

178 ions of TSP-1 mRNA that regulate coupling of TSP-1 mRNA to polysomes and its translation.

179 In these mice, deletion of TSP-1 ameliorated loss in volume and mass of the moderat

180 ogical assessment indicated that deletion of TSP-1 reduced inflammatory cell infiltration of muscle f

181 expression levels and tissue distribution of TSP-1.

182 ort that the von Willebrand type C domain of TSP-1 is likely responsible for this BMP-2/4-binding act

183 agent based on the antiangiogenic domain of TSP-1, designated 3TSR (for three TSP-1 type 1 repeats),

184 the high affinity heparin-binding domain of TSP-1, designated TSPN-1, in association with the synthe

185 The inhibitory effect of TSP-1 on cAMP signaling could be reproduced with a pepti

186 The effects of TSP-1 on GlyRs were dependent on the activation of excit

187 We investigated the effects of TSP-1 on neurons with mature synapses using immunocytoch

188 ding sequence of TSP-1, while the effects of TSP-1 were prevented by a CD36 blocking antibody.

189 unding C-terminal and N-terminal elements of TSP-1 and interact with other extracellular molecules.

190 es as the predominant sites of expression of TSP-1 in IR injury and showed colocalization of TSP-1 wi

191 viously reported the increased expression of TSP-1 in the large arteries of diabetic animals.

192 st that U19/EAF2 regulates the expression of TSP-1 via blocking p53 repression of the TSP-1 promoter.

193 the eye is dependent on their expression of TSP-1.

194 of VEGF and IL-8 and decreased expression of TSP-1.

195 is that mimic the antiangiogenic function of TSP-1.

196 gene requires the p53-dependent induction of TSP-1 and the shut down of angiogenesis.

197 of AT1Ra and treatment with an inhibitor of TSP-1.

198 provide new insights into the involvement of TSP-1 in the BMP-2/-4 mechanisms of action.

199 Knockdown of TSP-1 resulted in a similar phenotype.

200 Lack of TSP-1 prevented lesion formation in hyperglycemic ApoE(-

201 In this context, physiological levels of TSP-1 appear to support VEGFR2 function on both the cell

202 First, we found that levels of TSP-1 are elevated in blood of non-ambulant dysferlinopa

203 LSs resulted in inverse expression levels of TSP-1 compared with NR4A2, IL-8, and VEGF.

204 T2 MRI parameters revealed that loss of TSP-1 modestly inhibited inflammation only in gluteal mu

205 Rotary shadowing electron microscopy of TSP-1 has shown elongation of the stalk and diminution o

206 matched by enhanced lymph node migration of TSP-1 null APCs posttransplantation.

207 Thus, modulation of TSP-1 expression is achieved through anti-tumor necrosis

208 that together make up the complex network of TSP-1 regulation both at the transcriptional and post-tr

209 Notably, overexpression of TSP-1 alone did not influence tumor growth.

210 In the presence of TSP-1, AMPARs were less stabilized at synapses, increasi

211 tains capillary sprouting in the presence of TSP-1.

212 Their production of TSP-1 is regulated by environmental signals that establi

213 RPE is controlled by untranslated regions of TSP-1 mRNA that regulate coupling of TSP-1 mRNA to polys

214 metabolic pathway mediates up-regulation of TSP-1 by high glucose.

215 The cell-specific regulation of TSP-1 suggests a potential mechanism for the aberrant an

216 istance, and identify txr1 as a regulator of TSP-1 production and an agent for its chemotherapeutic m

217 In addition, release of TSP-1 was stimulated by ATP and UTP but not by 2-methylt

218 es unique regions of three type-I-repeats of TSP-1 and used engineered human neural stem cells (hNSC)

219 Similarly, the restoration of TSP-1 alone in p53 negative tumors resulted in the shut

220 These results suggest a role of TSP-1 in controlling the balance between excitation and

221 To confirm a direct role of TSP-1 in diabetic atherosclerosis, hyperglycemic TSP-1(-

222 The deleterious role of TSP-1 in ischemic kidney injury was demonstrated directl

223 To study the role of TSP-1 in remodeling of the diabetic heart, we generated

224 (ApoE(-/-)) mice and elucidated the role of TSP-1 in this process.

225 ticipates in the production and secretion of TSP-1.

226 eptide possessing a CD36 binding sequence of TSP-1, while the effects of TSP-1 were prevented by a CD

227 Macrophages are a source of TSP-1, which they produce in response to TLR4 mediated s

228 lantation, as the cornea is a rich source of TSP-1.

229 mRNAs, suggesting that the stabilization of TSP-1 may be part of a larger novel mechanism.

230 -specific posttranscriptional suppression of TSP-1 production in response to high glucose in microvas

231 -transfection blocked the p53 suppression of TSP-1 promoter.

232 Cellular synthesis of TSP-1 is tightly regulated by different intermediate bio

233 on of VEGF and IL-8 and with upregulation of TSP-1 expression.

234 umor growth, in part through upregulation of TSP-1.

235 , as well as those in the periphery of older TSP-1 null mice, secrete interleukin-17A, a cytokine ass

236 I and B7 maturation markers were detected on TSP-1 null APCs during inflammation.

237 Decrease of Txr1 or treatment with TSP-1 or TSP-1 mimetic peptide sensitized cells to taxane cytotox

238 nd are deficient in either integrin beta8 or TSP-1, known activators of latent TGF-beta1.

239 the in vitro studies, suppression of CD47 or TSP-1 expression in newborn mice by a novel in vivo smal

240 b or knocking down the expression of CD47 or TSP-1, but not signal regulatory protein alpha by small

241 /-) cells was reversed by ROCK inhibition or TSP-1 immunoneutralizing antibodies.

242 V600E) cells in which either B-Raf(V600E) or TSP-1 were knocked down were implanted orthotopically in

243 me PCR analysis of retina derived from WT or TSP-1 null mice at various time intervals after light- o

244 in part, through activation of the HER2-p38-TSP-1 pathway and inhibition of the HER2-PI3K-AKT-VEGF/I

245 ardiac fibroblasts populating collagen pads, TSP-1 incorporation into the matrix did not activate tra

246 demonstrate that, through this new pathway, TSP-1 is responsible for the remote AC-mediated recovery

247 found to be refractory to anti-proliferative TSP-1 signaling via a CD36-dependent mechanism.

248 Addition of purified TSP-1 to normal kidney proximal tubule cells or cells su

249 increased vascularity is mediated by reduced TSP-1 and TSP-2 levels and causes delayed tumor growth r

250 Ectopic NR4A2 expression led to reduced TSP-1 mRNA and protein levels with concomitant increases

251 herefore plays a dominant role in regulating TSP-1 production in the target organ during acute inflam

252 Compared with WT retina, TSP-1 null retina fails to recover from the laser-induce

253 lso involve TSPN-1 domains from two separate TSP-1 molecules.

254 led to the design of the first serum stable TSP-1 mimetic agonist peptide able to trigger selective

255 In summary, TSP-1 appears to play an accessory role in modulating Mp

256 ing and repressing the metastasis suppressor TSP-1.

257 Targeting TSP-1-dependent activation of TGF-beta could thus be a t

258 The four C-terminal TSP-1-like repeats of ADAMTS-12 are shown to be necessar

259 We conclude that TSP-1 expression can be regulated by activation of P2Y r

260 We conclude that TSP-1 production in endothelial cells depends on not onl

261 hat stimulates release of ATP, we found that TSP-1 expression increased after mechanical strain and w

262 We show here that TSP-1-mediated TGF-beta1 activation plays an important r

263 d healthy controls, supporting the idea that TSP-1 levels are correlated with disease progression.

264 Taken together, the results indicate that TSP-1 and 3TSR modulate the function of VEGFR2.

265 Together, these results indicate that TSP-1 deficiency results in a spontaneous form of chroni

266 the phosphorylation of VASP, indicating that TSP-1 modulated the cAMP/PKA signaling events through a

267 We propose that TSP-1 could regulate bioavailability of BMPs, either pro

268 We propose that TSP-1 is a novel regulator of ischemic damage in the kid

269 use model of lung cancer, we have shown that TSP-1 plays a critical and cell-autonomous role in suppr

270 assertion based on sequence similarity that TSP-1 shares with the von Willebrand type C domain of Cr

271 within the developing CNS, and suggest that TSP-1 and -2 act as a permissive switch that times CNS s

272 These data suggest that TSP-1 may be a mediator of capillary regression with det

273 We show in transplantation that TSP-1 inhibits T cell allosensitization and consequently

274 d p38 activation and SB203580 attenuated the TSP-1 upregulation induced by trastuzumab.

275 ication of 4N1K decapeptide derived from the TSP-1/CD47 binding epitope.

276 n of NR4A2 levels resulted in a shift in the TSP-1/VEGF expression ratio.

277 letion studies identified a 5' region of the TSP-1 promoter repressed by NR4A2 and proangiogenic tran

278 of TSP-1 via blocking p53 repression of the TSP-1 promoter.

279 fection alone had little or no effect on the TSP-1 promoter.

280 The Tb3+ binding constants placed the TSP-1 region affected by N700S polymorphism among other

281 orter assay, p53 transfection suppressed the TSP-1 promoter activity and U19/EAF2 co-transfection blo

282 -positive blood vessels, suggesting that the TSP-1 down-regulation can contribute to increased angiog

283 In this study, we have found that the TSP-1 receptors CD36 and beta1 integrin associate with t

284 rase expression through interaction with the TSP-1 3'UTR at both the mRNA and protein levels.

285 Treatment with the TSP-1-derived peptide was associated with down-regulatio

286 GF in the synovium, after treatment with the TSP-1-derived peptide were studied in the peptidoglycan-

287 We have identified a region within the TSP-1 type 3 repeats that inhibits human neutrophil elas

288 These results suggest that therapeutic TSP-1 inhibition may have important atheroprotective pot

289 This TSP-1-derived synthetic peptide may represent an importa

290 investigate the therapeutic benefit of this TSP-1-derived peptide sequence and its effect on connect

291 domain of TSP-1, designated 3TSR (for three TSP-1 type 1 repeats), has significant antiangiogenic an

292 In summary, we identified for the first time TSP-1 as a BMP-2/-4 antagonist and presented a structura

293 al role of CD47 in the cellular responses to TSP-1 was demonstrated further using inhibitory antibodi

294 revealed by comparing wild-type (WT) versus TSP-1 null allografts in corneal transplantation, as the

295 In vitro, TSP-1 stimulation increased macrophage, but not endothel

296 recruitment of circulating monocytes, while TSP-1 inhibition or knockout bone marrow prevents TGF-be

297 hagocytic activity, which is consistent with TSP-1-enhanced phagocytosis and pro-inflammatory cytokin

298 ng machinery and specifically interacts with TSP-1 mRNA through its 3'UTR.

299 then crossed dysferlinopathic BlaJ mice with TSP-1 knockout mice and assessed disease progression lon

300 Decrease of Txr1 or treatment with TSP-1 or TSP-1 mimetic peptide sensitized cells to taxan